Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 7,024 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Volunteers. Clear all

Conditions: Blindness
Interventions: Magstim Rapid Magnetic Stimulator; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pharmacokinetics of ASKP1240, Healthy Volunteers
Interventions: ASP1240, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid, Glucocorticoid
Interventions: Mifepristone, Placebo, Spironolactone, Combined, Dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriasis
Interventions: ABBV-157, Placebo for ABBV-157; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more

Conditions: Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
Interventions: ABBV-932, Placebo for ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey

Conditions: Healthy
Interventions: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HIV, ICL, Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer Disease
Interventions: BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertension, Healthy
Interventions: ViTrack, Oscillometric BP Device, Auscultatory cuff; Device
Lead sponsor: Dynocardia, Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Healthy Volunteers
Interventions: [14C]-brensocatib; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: Cendakimab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Allergy Skin, Allergy, Dermatitis, Allergic Contact
Interventions: NeoMatriX Wound MatriX Collagen Dressing; Device
Lead sponsor: NeXtGen Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy, Elderly
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Volunteers
Interventions: LY2605541; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: simvastatin plus albiglutide; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Restless Legs Syndrome (RLS)
Interventions: gabapentin enacarbil, diphenhydramine, placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hepatic Impairment
Interventions: CMX001; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Conditions: Healthy
Interventions: K-001, K-877-ER, CSG452; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy, Vitamin D Deficiency
Interventions: ergocalciferol, placebo pill; Dietary Supplement · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 9 Years to 18 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: biologic sample preservation procedure, medical chart review, questionnaire administration; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteer
Interventions: DISC-0974, Placebo; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Subjects
Interventions: lemborexant, Loestrin, famotidine, fluconazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Osteoporosis
Interventions: Teriparatide; Drug
Lead sponsor: Pfenex, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Depressive Disorder, Major
Interventions: Desvenlafaxine Sustained Release (DVS SR); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Brain Plasticity of Verbal Memory in the Blind

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions

Tissue Biopsy and Imaging Studies in HIV-Infected Patients

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

A Study of LY2605541 in Healthy Participants and in the Elderly

A Drug Interaction Study of Simvastatin and Albiglutide

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

Vitamin D Deficiency in Adolescent Girls

Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

A Comparison Study of PF708 and Forteo in Healthy Subjects

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)